Cell & Gene Therapy, APIs
Total Trials
9
As Lead Sponsor
As Collaborator
0
Total Enrollment
3,444
NCT02341391
Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 28, 2007
Completion: Sep 30, 2008
NCT02341378
Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis
Phase: Phase 2
Start: Aug 31, 2009
Completion: Oct 31, 2010
NCT01671072
Start: Jul 31, 2011
Completion: Jan 31, 2013
NCT01825811
Efficacy and Safety Study of TissueGene-C Mixed With Fibrin-glue for the Patients With Degenerative Arthritis
Start: Oct 31, 2012
Completion: Jun 30, 2014
NCT02072070
Phase: Phase 3
Start: Nov 30, 2013
Completion: Aug 31, 2015
NCT03412864
A Post Marketing Surveillance Study of INVOSSA K Inj.
Phase: N/A
Start: Jul 12, 2017
Completion: Jul 11, 2023
NCT03383471
The Efficacy and Safety of Invossa K Injection in Patients Diagnosed With Knee Osteoarthritis
Start: Feb 12, 2018
Completion: Mar 30, 2020
NCT04238793
Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
Phase: Phase 1/2
Start: Apr 16, 2020
Completion: Oct 18, 2023
NCT05613569
A Long-term, 3-Year, Follow-up Study for Patients Completing the KS-GIG-001-01 Study
Start: Jul 26, 2022
Completion: Apr 30, 2027
Loading map...